In his hearing with the European Parliament, John Dalli promised the reassessment of the “Information to Patients” proposal. Yet, the proposals are moving through the political process in the Parliament. In this context, EPHA sent a letter to Commissioner Dalli. In the letter, EPHA called on his services to handle the dossier urgently in order to clarify uncertainties in the legislative process. Below is the full text of the letter.
Mr. John Dalli
European Commissioner for Health and Consumer Policy
European Commission
B-1049 Brussels
Brussels, 14 April 2010
Dear Commissioner Dalli,
On behalf of the European Public Health Alliance and further to our previous communications, we are writing to you in relation to the European Commission approach to the “Information to patients” proposed directive.
As you know, the public health community had been long advocating for the responsibility for pharmaceutical policy to be given to the European Commissioner responsible for health policy. With the bold decision taken by President Barroso, we place very high hopes on the outcome of your mandate, as the first Commissioner for Health and Consumer Policy bearing responsibility for pharmaceutical policy as well.
During your hearing at the European Parliament, you announced your intention to reassess the proposals on “information to patients”- a political commitment that we immediately welcomed! We would strongly support you in making this commitment a reality in the immediate future. We are concerned that the file is continuing to be debated in the European Parliament despite the lack of support for this proposal from the Member States as well as the public health community, in its current format.
We would support you in a process of reassessment and are ready to contribute in a constructive manner to its quick development, as an opportunity to “put patients and consumers first”.
Whilst the current proposed directive does not meet the needs of citizens for relevant, independent and comparative health information tailored to users, we would like to put forward a series of key points from a public health perspective that would considerably improve access to patient information for European citizens in the future:
– 1. Ensure that the difference between marketing, of and information on, medicinal products is clearly established and that the roles between the pharmaceutical companies and other actors in the healthcare sector in this matter are clarified. This means fully implementing and enforcing the European regulation on pharmaceutical promotion, including measures to ensure that article 88 of Directive 2001/83/EC, is not weakened or undermined.
– 2. Ensure that pharmaceutical companies consistently abide by their obligations relative to drug packaging and patient leaflets. This means consulting with target patients groups , guaranteeing that patients’ leaflets are readable. On this point, we would like to emphasise the work carried out by the European Medicines Agency on that matter. This provision would ensure that officially approved leaflets are more useful and accessible to their target audience: patients;
– 3. Invest in communication between patients and health professionals: informing patients and helping them meet their needs requires a relationship of trust and interpersonal dialogue. These are the core responsibilities of the healthcare professions. This means investing in the collaboration between patients and healthcare professional organizations. In addition, it needs to be embedded into education and continuous professional development of healthcare professionals. Healthcare professionals should also receive the necessary tools to enable them to provide adequate and timely information to patients;
– 4. Encourage national agencies to become proactive and more transparent providers of information so as to guarantee full public access to data on the efficacy and safety of medicines and other healthcare products both before and after a product is marketed. Joint actions that could support them should be encouraged ;
– 5. Develop and reinforce existing sources of comparative, unbiased information on pharmacological or non pharmacological treatment choices and make them publicly available. We particularly welcome the Eudravigilance database as a good practice.
We remain at your disposal for further support and contributions and look forward to learning about your concrete next steps in relation to the reassessment of this proposal for the benefit of European citizens.
Yours sincerely,
-Monika Kosińska
-Secretary General
